Response to Emerging Infection Leading to Outbreak of Linezolid-Resistant Enterococci
Published Date:Jul 2007
Source:Emerg Infect Dis. 13(7):1024-1030.
Colony Count, Microbial
Communicable Diseases, Emerging
Drug Resistance, Bacterial
Drug Utilization Review
Gram-Positive Bacterial Infections
Length Of Stay
Microbial Sensitivity Tests
Description:Linezolid was approved in 2000 for treatment of gram-positive coccal infections. We performed a case-control study during a hospital outbreak of linezolid-resistant enterococci (LRE) infections, comparing cases of LRE infection (cases) with linezolid-sensitive enterococci infections (controls). Nasal and perirectal swab samples were obtained from all patients in a 1-day point-prevalence survey. We examined antimicrobial drug use and calculated the defined daily dose of linezolid per 1,000 patient-days. Fifteen LRE cases were identified (13 Enterococcus faecalis and 2 E. faecium); 7 were vancomycin-resistant. Compared with controls, case-patients had increased in-hospital mortality rates and lengths of stay. Multivariate analysis identified independent predictors of LRE infection: prior cultures positive for methicillin-resistant Staphylococcus aureus (adjusted odds ratio [AOR] 27), hospitalization duration before index culture (AOR 1.1 per day), and duration of preceding linezolid therapy (AOR 1.1 per day). Linezolid exposure and patient-to-patient transmission appear to be responsible for LRE infections, an important emeraina hospital problem.
image/gif image/jpeg image/gif image/jpeg image/gif image/jpeg image/gif image/jpeg application/pdf text/plain text/plain
You May Also Like: